Develops drugs for schizophrenia.
Dec 2024Revenue $0.00/yrExpenses $21.8M/yr
No trendCash runway ≈ 2.9 years from Jun 2026
Figures by year
When will Minerva Neurosciences be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2024, revenue was $0.00 and expenses $21.8M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2024 | $0.00 | $21.8M | −$21.8M |
| Dec 2023 | $0.00 | $23.1M | −$23.1M |
| Dec 2022 | $0.00 | $25.2M | −$25.2M |
| Dec 2021 | $0.00 | $45.4M | −$45.4M |
| Dec 2020 | $0.00 | −$1.85M | $1.85M |
| Dec 2019 | $0.00 | $75.9M | −$75.9M |
| Dec 2018 | $0.00 | $51.7M | −$51.7M |
| Dec 2017 | $0.00 | $41.2M | −$41.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.